Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults.
Valproic acid (VPA) has the potential to benefit patients suffering from human immunodeficiency virus (HIV)-associated cognitive impairment. The purpose of this study was to determine if VPA affects the plasma concentration of efavirenz (EFV) or lopinavir. HIV type 1 (HIV-1)-infected patients receiving EFV or lopinavir-ritonavir (LPV/r) had 9 or 10 blood samples drawn over 8 to 24 h of a dosing interval at steady state before and after receiving 250 mg of VPA twice daily for 7 days. VPA blood samples drawn before (C(0)) and 8 h after the morning dose (8 h) were compared to blood samples from a group of HIV-1-infected subjects who were taking either combined nucleoside reverse transcriptase inhibitors alone or had discontinued antiretroviral therapy. Pharmacokinetic parameters were calculated by noncompartmental analysis, and tests of bioequivalence were based on 90% confidence intervals (CIs) for ratios or differences. The geometric mean ratio (GMR) (90% CI) of the areas under the concentration-time curve from 0 to 24 h (AUC(0-24)s) of EFV (n = 11) with and without VPA was 1.00 (0.85, 1.17). The GMR (90% CI) of the AUC(0-8)s of LPV (n = 8) with and without VPA was 1.38 (0.98, 1.94). The differences (90% CI) in mean C(0) and 8-h VPA concentrations versus the control (n = 11) were -1.0 (-9.4, 7.4) microg/ml and -2.1 (-11.1, 6.9) microg/ml for EFV (n = 10) and -5.0 (-13.2, 3.3) microg/ml and -6.7 (-17.6, 4.2) microg/ml for LPV/r (n = 11), respectively. EFV administration alone is bioequivalent to EFV and VPA coadministration. LPV concentrations tended to be higher when the drug was combined with VPA. Results of VPA comparisons fail to raise concern that coadministration with EFV or LPV/r will significantly influence trough concentrations of VPA.
DiCenzo
Robert
R
University of Rochester Medical Center, Clinical Pharmacology Unit, 601 Elmwood Ave., Box 315, Room 1.6124, Rochester, NY 14642, USA. robert_dicenzo@urmc.rochester.edu
Peterson
Derick
D
Cruttenden
Kim
K
Morse
Gene
G
Riggs
Garret
G
Gelbard
Harris
H
Schifitto
Giovanni
G
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000097:blood*; D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use; D019540:Area Under Curve; D048588:Benzoxazines; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology; D003521:Cyclopropanes; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000523:psychology; D006207:Half-Life; D006801:Humans; D061466:Lopinavir; D008297:Male; D010078:Oxazines / Q000097:blood*; D011744:Pyrimidinones / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000097:blood*; D014635:Valproic Acid / Q000494:pharmacology* / Q000627:therapeutic use
D000480:Alkynes; D019380:Anti-HIV Agents; D000927:Anticonvulsants; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; D014635:Valproic Acid; C098320:efavirenz